Taro NonSpil
This article was originally published in The Tan Sheet
Executive Summary
Recent in-store demonstrations at Wal-Mart of Taro Pharmaceuticals' NonSpil drug delivery system were "met with huge and great reception from consumers," CFO Kevin Connelly comments at CIBC World Markets Healthcare Conference in New York City Nov. 12. Firm may conduct more demonstrations in Wal-Mart stores later this year or early next year, Connelly says. Taro is working on licensing agreements for NonSpil, the exec reports, adding that the firm will "have more growth opportunity...to license it on the prescription side" as possibility to extend the patent life of Rx drugs (1"The Tan Sheet" Sept. 15, 2003, p. 4). Sales of Taro's ElixSure line of cough/cold medicines for children, which was shipped in June and uses the NonSpil technology, are doing "very well," though "it is too early to tell" if the launch is a complete success, according to Connelly...
You may also be interested in...
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.